Table 2.

Genotype and allelic frequency distribution of rs1800629 and rs1799964 polymorphisms among patients and controls

rs1800629	GG	GA	AA	G	A	Comparison of groups	OR (95 % CI)	P-value
	N (%)	N (%)	N (%)
Controls (306)	10 (3)	293 (96)	3 (1)	0.51	0.49	GG vs. GA + AA	1.29 (0.55–3.04)	0.55
Patients (283)	10 (4)	270 (95)	3 (1)	0.52	0.48	GA vs. GG + AA	0.80 (0.37–1.72)	0.56
	χ 2 = 0.1; p = 0.95			χ 2 = 0.02;p = 0.88		AA vs. GG + GA	1.07 (0.21–5.35)	0.93
HWE	Patients	χ 2 = 233.98; p = <0.05				G vs. A	1.04 (0.59–1.81)	0.88
	Controls	χ 2 = 256.77; p = <0.05
rs1799964	TT	TC	CC	T	C	Comparison of groups	OR (95 % CI)	p-value
	N (%)	N (%)	N (%)
Controls (306)	162(53)	139(45)	5(2)	0.76	0.24	TT vs. TC + CC	0.54(0.38–0.75)	<0.01*
Patients (283)	107(38)	170(60)	6(2)	0.68	0.32	TC vs. TT + CC	1.81 (1.30–2.51)	<0.01*
	χ 2 = 12.79; p  = 0.001*			χ 2 = 1.21;p = 0.27		CC vs. TT + TC	1.30 (0.39–4.32)	0.76
HWE	Patients	χ 2 = 40.17; p = <0.05				T vs. C	0.67 (0.36–1.25)	0.27
	Controls	χ 2 = 16.62; p = <0.05

OR odds ratio, CI class interval, HWE Hardy Weinberg Equilibrium

*Significant at 5 % LOS